Status:
COMPLETED
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather t...
Eligibility Criteria
Inclusion
- no prior treatment for metastatic disease
- PS 0-2
- measurable disease
Exclusion
- neuropathy \> or equal to grade 2
- concomitant radiation therapy or other systemic cancer therapies
- brain mets
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00205322
Start Date
April 1 2004
End Date
October 1 2007
Last Update
November 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792